Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30131466 | 1.00 | KMT2A (0.69) | KMT2AHIF1ASMN1; SMN2EPHX2HTT | |
| SCHEMBL11818472 | 0.91 | HIF1A (0.67) | KMT2AHIF1ASMN1; SMN2EPHX2HTT | |
| SCHEMBL11487228 | 0.90 | KMT2A (0.61) | KMT2AHIF1ASMN1; SMN2EPHX2HTT | |
| SCHEMBL9341104 | 0.86 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL31658991 | 0.86 | KMT2A (0.83) | KMT2ASMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL11770320 | 0.86 | HIF1A (0.60) | KMT2AHIF1ASMN1; SMN2EPHX2HTT | |
| SCHEMBL8722345 | 0.84 | KMT2A (0.65) | KMT2ASMN1; SMN2EPHX2RAB9ANPC1 | |
| SCHEMBL6072210 | 0.84 | HIF1A (0.59) | HIF1ASMN1; SMN2KDM4EMAPTRAB9A | |
| SCHEMBL3083971 | 0.83 | HTT (0.75) | KMT2ASMN1; SMN2EPHX2HTTKDM4E | |
| SCHEMBL29733373 | 0.83 | HTT (0.75) | KMT2ASMN1; SMN2EPHX2HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| EP-0901488-B1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| EP-0901488-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997043277-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-20 | — | — | WO | disclosed |
| US-4659716-A | Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines | SCHERING CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | KMT2A 956/4885HIF1A 567/4885SMN1; SMN2 807/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | KMT2A 3331/4885HIF1A 4300/4885SMN1; SMN2 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.